Regeneron Reports Second Quarter 2021 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Regeneron (REGN) Tops Q2 EPS by $8.11, Sales Pounce Consensus
August 5, 2021 6:33 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $25.80, $8.11 better than the analyst estimate of $17.69. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $3.89 billion.
Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COVTM(2); revenues excluding REGEN-COV(1)(2) increased 22%Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billionSecond quarter 2021 Dupixent® global net sales(3), which are recorded by Sanofi, increased 59% to... More